FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891517512> ?p ?o ?g. }

• W2891517512 endingPage "102" @default.
• W2891517512 startingPage "97" @default.
• W2891517512 abstract "Introduction Unprovoked venous thromboembolism (VTE) may be the first manifestation of an undiagnosed cancer. We assessed the cost-effectiveness of 18F-Fluorodesoxyglucose Positron Emission/Computed Tomography (FDG PET/CT) plus limited screening and limited screening strategies in patients with unprovoked VTE from the perspectives of the Ontario (Canada) and French health care systems. Methods We conducted a cost-effectiveness analysis based on a published randomized controlled trial of 394 patients aged 18 years or older who were diagnosed with unprovoked VTE. We obtained data with respect to efficacy and health care utilization from the published trial. The primary measure of effectiveness was the number of avoided cases of delayed cancer diagnosis and the secondary measure of effectiveness was the quality adjusted life year (QALY) at the end of the study in each group. We used generalized linear models to estimate incremental cost-effectiveness ratios (ICER) while controlling for patient demographic and clinical characteristics. Results were presented as the incremental cost to avoid one case of delayed cancer diagnosis and the incremental cost per QALY gained. The 95% confidence intervals (CIs) were estimated using bootstrap re-sampling procedures with 5000 iterations. Results Compared to a limited screening strategy, the ICER of limited strategy plus FDG PET/CT scan was C$ 26,840.19 (95% CI: C$ 24,046.51; C$ 34,581.53) per one avoided case of delayed cancer diagnosis from the Ontario health system perspective and €16,370.45 (95% CI: € 9904.48; € 39,578.91) per one avoided case of delayed cancer diagnosis from the French health system perspective. The probabilities that addition of FDG PET/CT to limited screening is cost-effective rose with increasing willingness to pay values. Compared with the limited screening, the extensive screening was associated with C$ 3412.85 per QALY gained (95% CI: 1463.89; −13,935.88) from the Ontario health system perspective and €2162.83 per QALY gained (95% CI 958.78; −10,544.42) from the French health system perspective. Conclusion Addition of a FDG PET/CT for occult cancer diagnosis was associated with better health outcomes (fewer cases of delayed cancer diagnosis and greater QALYs) and a higher cost from the perspective of publicly funded health care systems; the cost-effectiveness results are however highly uncertain." @default.
• W2891517512 created "2018-09-27" @default.
• W2891517512 creator A5002791203 @default.
• W2891517512 creator A5020323780 @default.
• W2891517512 creator A5024267268 @default.
• W2891517512 creator A5024863302 @default.
• W2891517512 creator A5030533594 @default.
• W2891517512 creator A5040363397 @default.
• W2891517512 creator A5045010479 @default.
• W2891517512 creator A5047152244 @default.
• W2891517512 creator A5051047770 @default.
• W2891517512 creator A5078027320 @default.
• W2891517512 date "2018-11-01" @default.
• W2891517512 modified "2023-10-17" @default.
• W2891517512 title "In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems" @default.
• W2891517512 cites W1937705451 @default.
• W2891517512 cites W1980874014 @default.
• W2891517512 cites W2004403992 @default.
• W2891517512 cites W2029767517 @default.
• W2891517512 cites W2035568195 @default.
• W2891517512 cites W2105054066 @default.
• W2891517512 cites W2111139930 @default.
• W2891517512 cites W2113953182 @default.
• W2891517512 cites W2139371467 @default.
• W2891517512 cites W2190659314 @default.
• W2891517512 cites W2253736303 @default.
• W2891517512 cites W2581793487 @default.
• W2891517512 cites W2590378396 @default.
• W2891517512 cites W2757730097 @default.
• W2891517512 cites W2789771941 @default.
• W2891517512 doi "https://doi.org/10.1016/j.thromres.2018.09.050" @default.
• W2891517512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30268859" @default.
• W2891517512 hasPublicationYear "2018" @default.
• W2891517512 type Work @default.
• W2891517512 sameAs 2891517512 @default.
• W2891517512 citedByCount "6" @default.
• W2891517512 countsByYear W28915175122019 @default.
• W2891517512 countsByYear W28915175122020 @default.
• W2891517512 countsByYear W28915175122021 @default.
• W2891517512 countsByYear W28915175122022 @default.
• W2891517512 crossrefType "journal-article" @default.
• W2891517512 hasAuthorship W2891517512A5002791203 @default.
• W2891517512 hasAuthorship W2891517512A5020323780 @default.
• W2891517512 hasAuthorship W2891517512A5024267268 @default.
• W2891517512 hasAuthorship W2891517512A5024863302 @default.
• W2891517512 hasAuthorship W2891517512A5030533594 @default.
• W2891517512 hasAuthorship W2891517512A5040363397 @default.
• W2891517512 hasAuthorship W2891517512A5045010479 @default.
• W2891517512 hasAuthorship W2891517512A5047152244 @default.
• W2891517512 hasAuthorship W2891517512A5051047770 @default.
• W2891517512 hasAuthorship W2891517512A5078027320 @default.
• W2891517512 hasConcept C112930515 @default.
• W2891517512 hasConcept C121608353 @default.
• W2891517512 hasConcept C126322002 @default.
• W2891517512 hasConcept C141071460 @default.
• W2891517512 hasConcept C168563851 @default.
• W2891517512 hasConcept C3019080777 @default.
• W2891517512 hasConcept C44249647 @default.
• W2891517512 hasConcept C64332521 @default.
• W2891517512 hasConcept C71924100 @default.
• W2891517512 hasConceptScore W2891517512C112930515 @default.
• W2891517512 hasConceptScore W2891517512C121608353 @default.
• W2891517512 hasConceptScore W2891517512C126322002 @default.
• W2891517512 hasConceptScore W2891517512C141071460 @default.
• W2891517512 hasConceptScore W2891517512C168563851 @default.
• W2891517512 hasConceptScore W2891517512C3019080777 @default.
• W2891517512 hasConceptScore W2891517512C44249647 @default.
• W2891517512 hasConceptScore W2891517512C64332521 @default.
• W2891517512 hasConceptScore W2891517512C71924100 @default.
• W2891517512 hasLocation W28915175121 @default.
• W2891517512 hasLocation W28915175122 @default.
• W2891517512 hasLocation W28915175123 @default.
• W2891517512 hasOpenAccess W2891517512 @default.
• W2891517512 hasPrimaryLocation W28915175121 @default.
• W2891517512 hasRelatedWork W1991263975 @default.
• W2891517512 hasRelatedWork W2005049219 @default.
• W2891517512 hasRelatedWork W2041145027 @default.
• W2891517512 hasRelatedWork W2043028331 @default.
• W2891517512 hasRelatedWork W2066175645 @default.
• W2891517512 hasRelatedWork W2115503673 @default.
• W2891517512 hasRelatedWork W2159627298 @default.
• W2891517512 hasRelatedWork W2187740012 @default.
• W2891517512 hasRelatedWork W3007581650 @default.
• W2891517512 hasRelatedWork W4288702852 @default.
• W2891517512 hasVolume "171" @default.
• W2891517512 isParatext "false" @default.
• W2891517512 isRetracted "false" @default.
• W2891517512 magId "2891517512" @default.
• W2891517512 workType "article" @default.